Skip to main content
. 2019 Aug 13;10(8):611. doi: 10.1038/s41419-019-1860-2

Fig. 1. Accumulation of CRL-regulated proteins in MLN4924-treated, carfilzomib-treated, and bortezomib-treated multiple myeloma cell lines.

Fig. 1

a Cells were challenged in technical triplicates for 24 h with the indicated concentrations of MLN4924, carfilzomib and bortezomib. Cell viability was determined using the MTT assay. b Cells were treated as indicated with MLN4924, carfilzomib, and bortezomib and total cell lysates were then analyzed for the presence of the indicated proteins by Western blotting. Data shown are representative of at least two independent experiments